From Wikipedia, the free encyclopedia

This article or section is written like an advertisement. Please help rewrite this article from a neutral point of view. Mark blatant advertising for speedy deletion, using {{db-spam}}.

Novo Nordisk A/S
Type	Public (OMX: NOVO B, NYSE: NVO)
Founded	1923
Headquarters	Bagsværd, Denmark
Key people	Sten Scheibye, Chairman Lars Rebien Sørensen, President & CEO Jesper Brandgaard, CFO
Industry	Pharmaceuticals, Healthcare
Products	Activelle, Levemir, NovoSeven
Revenue	38.743 billion DKK or $6.9 billion USD (2006) [1]
Employees	23,172 (2006)
Website	www.novonordisk.com

Novo Nordisk (OMX: NOVO B, NYSE: NVO) manufactures and markets pharmaceutical products and services. Founded in Denmark in 1923, the company has since become a world leader in diabetes care with one of the broadest diabetes product portfolios in the industry, including the products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position in areas such as haemostasis management, growth hormone therapy and hormone replacement therapy.

With headquarters in Denmark, Novo Nordisk has production facilities in six countries, with affiliates or offices in 68 countries. Novo Nordisk employs 23,172 people globally (as of 2006) [2].

Novo Nordisk claims to be dedicated to developing its business towards ecological, social and economic sustainability. The company says this commitment is demonstrated through its values and its environmental and social responsibility policies also called the triple bottom-line, although some question the authenticity of this given the company's aggressive pursuit of profits.

The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt. The Apis bull was worshipped as the incarnation of Ptah, creator of the universe, city god of Memphis and the patron deity of craftsmen.

The logo is a stylised reproduction of an Egyptian statuette dating from circa 664–323 BC. It is richly ornamented with symbols representing, among other things, the eternal dualities of life, day and night, life and death.

The Apis bull has been Novo’s logo since the year after the company’s foundation. The choice of the logo follows an old European chemist's tradition of identifying pharmacies by an animal symbol.

Novo Nordisk A/S is a firm follower of the 'triple bottom line'. As part of this ideal, as well as being a global leader in Diabetes care, Novo Nordisk have sponsored the International Diabetes Federation's Unite for Diabetes campaign — a campaign that has successfully achieved a UN Resolution on Diabetes.

As such, they have also launched the Novo Nordisk Changing Diabetes World Tour — a truck that folds out into an educational and awareness-developing bus. The vehicle was launched in Copenhagen in September 2005 and has visited Europe, Africa, and Australia.

Ragaglitazar is a novel dual peroxisome proliferator-activated receptor (PPAR) and agonist intended to restore insulin sensitivity and correct diabetic dyslipidemia, which was created by Novo Nordisk in 2001. During the clinical testing that took place in India, Novo Nordisk did not complete preliminary testing of Ragaglitazar on animals before moving on to human testing. While administering the drug to humans, Novo Nordisk and its research scientists recognized urinary bladder tumors on the rats that were given Ragaglitazar during the animal test and therefore stopped all human testing and trials. A statement was then released by the company in 2003: “Novo Nordisk's decision was taken in response to findings of urine bladder tumors in one mouse and a number of rats treated with Ragaglitazar. All current clinical trials involving Ragaglitazar have been stopped and all planned new clinical trials have been postponed, while preliminary data from studies in rats and mice are being investigated." It is regulated by law that all preclinical or preliminary trials must be complete for the FDA to approve the drug testing to be performed on humans. Novo Nordisk failed to do this when they were developing Ragaglitazar.

Novo Nordisk was created in 1989 through a merger between two Danish companies – Novo Industri A/S and Nordisk Gentofte A/S.

• 1923 Nordisk Insulinlaboratorium (later Nordisk Gentofte) founded.
• 1925 Novo Terapeutisk Laboratorium (later Novo Industri) founded.
• 1932 Nordisk Insulinlaboratorium founds the Steno Memorial Hospital.
• 1938 Novo founds Hvidøre Diabetes Sanatorium.
• 1941 Novo launches its first enzyme, trypsin, extracted from the pancreas of animals and used for bating leather before tanning.
• 1946 Nordisk develops Isophane insulin NPH insulin, a neutral insulin with prolonged action.
• 1947 Penicillin Novo is launched – Novo’s first product to be manufactured through fermentation.
• 1953 Lente® – a long-acting insulin zinc suspension – is launched.
• 1963 Alcalase® – Novo’s first detergent enzyme produced by fermentation.
• 1973 Nordisk Gentofte markets Nanormon® growth hormone for the treatment of growth hormone insufficiency. The growth hormone is extracted from human pituitary glands.
• 1973 Monocomponent (MC) insulin is introduced – the purest insulin available.
• 1974 Novo’s B shares are quoted on the Copenhagen Stock Exchange.
• 1977 Trisequens® – sequential combined oral hormone replacement therapy (HRT) for peri-menopausal women – is marketed.
• 1981 Novo becomes the first company in Scandinavia to be quoted on the New York Stock Exchange.
• 1982 Human Monocomponent insulin is launched – the world’s first insulin preparation identical to human insulin. It is extracted from the pancreas of pigs and converted to human insulin.
• 1985 NovoPen® – an injection system similar in appearance to a fountain pen, with replaceable insulin cartridges – is launched.
• 1987 Novo starts production of human insulin with the help of genetically engineered yeast cells.
• 1988 Nordisk Gentofte markets Norditropin® genetically engineered human growth hormone.
• 1989 Novo Industri A/S and Nordisk Gentofte A/S merge to become the world’s leading producer of insulin.
• 1989 NovoLet® – the world’s first prefilled insulin syringe – is marketed.
• 1992 The Steno Memorial Hospital and Hvidøre Hospital merge to form the Steno Diabetes Center.
• 1994 Novo Nordisk is the first company in Denmark – and one of the first in the world – to publish an environmental report.
• 1996 NovoSeven® – for the treatment of haemophilia patients with inhibitor reaction – is launched.
• 1998 NovoNorm®/Prandin®, a new oral treatment for type 2 diabetes, is launched in the US and a number of European countries.
• 1998 Activelle® – the first low-dose continuous combined oral HRT for post-menopausal women – is introduced.
• 1999 Novo Nordisk publishes its first social report.
• 1999 Innovo®, the world’s first insulin doser with a built-in electronic memory, is launched in Europe.
• 1999 NovoRapid® (NovoLog® in the US) – a rapid-acting insulin analogue – is marketed.
• 1999 Norditropin® SimpleXx® – the world’s first liquid growth hormone in a dedicated pen system – is launched.
• 2000 Novofem®, a low-dose sequential combined oral HRT, is marketed in Germany. Two years later it is launched in several other European countries.
• 2000 Novo Nordisk is split into three separate companies operating under the umbrella of the Novo Group: Novo Nordisk A/S, Novozymes A/S and Novo A/S.
• 2001 InnoLet® – the first insulin delivery system specially designed to suit the needs of insulin users with poor eyesight and reduced dexterity – is launched.
• 2001 InDuo® – the world’s first combined blood glucose monitor and insulin injection system – is introduced.
• 2001 NovoRapid® FlexPen® and Insulatard® (NPH) FlexPen® are marketed. FlexPen® is a new prefilled pen, designed to be easy and discreet to use.
• 2001 Novo Nordisk acquires the controlling interest in the Brazilian pharmaceutical company Biobrás.
• 2002 NovoMix® 30 FlexPen® and NovoMix® Penfill® are introduced. NovoMix® 30 is a dual-release insulin analogue.
• 2004 Levemir® – a long-acting insulin analogue – is launched.

• Novo Nordisk Servicepartner
• Novo Nordisk Engineering
• NNIT (formerly Novo Nordisk IT)

• Novo Nordisk Website
  
• Novo Nordisk Changing Diabetes World Tour
• Novozymes A/S Website
• NNIT Website
• Novo Nordisk Servicepartner A/S Website
• NNE Website
• Novo A/S Website
• Novo Nordisk Foundation Website
• Novo Nordisk Biotech Fund Website

v • d • e OMX Copenhagen 20 companies of Denmark
A.P. Møller-Mærsk · Carlsberg · Coloplast · Dampskibsselskabet TORM · Danisco · Danske Bank · DSV · FLSmidth & Co. · GN Store Nord · Genmab · Lundbeck · Nordea · Novo Nordisk · Novozymes · Sydbank · Topdanmark · TrygVesta · Vestas Wind Systems · William Demant